Redeye comments on Avensia’s November sales figures.
Gofore just announced it is joining forces with an AI-focused niche company, founded by key employee...
Aktia’s Q3 showed that frequent changes during 2025 did not have a visible impact on the bank; on th...
On 11 December 2025, Hella announced its first series production order for High-Resolution Radar (HR...
The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell p...
* Careium states that it will not meet FY'25 outlook.
Redeye comments on Optomed’s directed share issue, raising EUR6.
I väntans tider med rekordkvartal i ryggen för Railcare: Nya uppdrag bör rulla in under vintern för ...
Redeye resumes coverage and updates its view on Gapwaves following the Q3 report and the completion ...
Systemair levererar sitt starkaste kvartal hittills med högre försäljning än väntat, stigande margin...
OssDsign this morning announces the appointment of Mark Waugh as new CEO, effective 1 January.
Redeye comments on the recently announced TetraGraph order from one of the leading NHS hospital trus...
Redeye updates its estimates and valuation after Surgical Science’s capital markets day.
After publishing strong data with BI-1808 yesterday, BioInvent returns with a positive readout with ...
Redeye leaves a comment following Cinclus’ announcement that its lead candidate, linaprazan glurate,...
